Skip to main content

Table 4 Comparison of administered treatments in patients with single and co-ingestant exposures to methadone

From: Clinical characteristics and time trends of hospitalized methadone exposures in the United States based on the Toxicology Investigators Consortium (ToxIC) case registry: 2010–2017

Variable

Total

Single exposure of methadone (n = 354)

Co exposure of Methadone with other drugs (n = 619)

Naloxone

Yes

442 (45.4%)

125 (35.3%)

317 (51.2%)

No

531 (54.6%)

232 (65.5%)

299 (48.3%)

N-acetylcysteine

Yes

40 (4.2%)

27 (7.6%)

13 (2.1%)

No

933 (95.8%)

330 (93.2%)

603 (97.4%)

Flumazenil

Yes

22 (2.3%)

9 (2.5%)

13 (2.1%)

No

951 (97.7%)

348 (98.3%)

603 (97.4%)

Sodium bicarbonate

Yes

21 (2.2%)

13 (2.77%)

8 (1.29%)

No

952 (97.8%)

344 (97.2%)

608 (98.2%)

Vasopressors

Yes

34 (3.5%)

26 (7.34%)

8 (1.29%)

No

939 (96.5%)

331 (93.5%)

608 (98.2%)

Anticonvulsants

Yes

13 (1.4%)

8 (2.3%)

5 (0.81%)

No

960 (98.6%)

349 (98.6%)

611 (98.7%)

Antipsychotics

Yes

25 (2.6%)

10 (2.8%)

15 (2.42%)

No

948 (97.4%)

347 (98.2%)

601 (97.1%)

Benzodiazepine

Yes

119 (12.3%)

66 (18.6%)

53 (8.56%)

No

854 (87.7%)

291 (81.5%)

563 (90.9%)

Opioids

Yes

38 (4.0%)

27 (8.22%)

11 (1.77%)

No

935 (96.0%)

330 (93.2%)

605 (97.7%)